Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union

BACKGROUND: Sodium oxybate (Xyrem(®)), approved by the European Medicines Agency (EMA) for narcolepsy with cataplexy, is only available through risk mitigation programs due to potential adverse effects including respiratory and central nervous system depression, neuropsychiatric events, and misuse....

Descripción completa

Detalles Bibliográficos
Autores principales: Iranzo, Alex, Serralheiro, Pedro, Schuller, Jan-Christof, Schlit, Anne-Françoise, Bentz, Jürgen W. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581670/
https://www.ncbi.nlm.nih.gov/pubmed/32989679
http://dx.doi.org/10.1007/s40801-020-00212-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581670/
https://www.ncbi.nlm.nih.gov/pubmed/32989679
http://dx.doi.org/10.1007/s40801-020-00212-9

Ejemplares similares